Drug
Octocrylene, Avobenzone
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Rebound Effect | 14 | 60.8 | 62.9 | signal |
| 2 | Pain Of Skin | 25 | 45.6 | 48.4 | signal |
| 3 | Rash Papular | 16 | 35.1 | 36.4 | signal |
| 4 | Skin Irritation | 32 | 34.3 | 37.1 | signal |
| 5 | Skin Burning Sensation | 47 | 32.5 | 36.5 | signal |
| 6 | Dermatitis Contact | 7 | 30.4 | 30.8 | signal |
| 7 | Dry Skin | 78 | 29.2 | 35.5 | signal |
| 8 | Skin Exfoliation | 48 | 28.4 | 31.9 | signal |
| 9 | Dermatitis Allergic | 7 | 27.7 | 28.1 | signal |
| 10 | Dermatitis | 11 | 26.1 | 26.8 | signal |
| 11 | Scab | 6 | 26.1 | 26.4 | signal |
| 12 | Rash Macular | 18 | 25.5 | 26.5 | signal |
| 13 | Eye Discharge | 5 | 24.1 | 24.4 | signal |
| 14 | Skin Fissures | 9 | 23.5 | 24.0 | signal |
| 15 | Eye Inflammation | 4 | 20.9 | 21.1 | signal |
| 16 | Erythema | 84 | 20.1 | 24.9 | signal |
| 17 | Acne | 31 | 20.0 | 21.5 | signal |
| 18 | Inflammatory Bowel Disease | 4 | 20.0 | 20.2 | signal |
| 19 | Application Site Pain | 5 | 11.2 | 11.3 | signal |
| 20 | Inappropriate Schedule Of Drug Administration | 16 | 10.9 | 11.3 | signal |
| 21 | Dermatitis Atopic | 8 | 7.9 | 8.0 | signal |
| 22 | Application Site Erythema | 3 | 5.6 | 5.6 | signal |